Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aditxt ( (ADTX) ) has provided an announcement.
Aditxt, Inc. announced the termination of its Arrangement Agreement with Appili Therapeutics, Inc., effective May 31, 2025. The decision was made after determining that the agreement was no longer strategically aligned with Aditxt’s goals, eliminating approximately $16 million in closing obligations. This move reflects Aditxt’s strategic realignment and could impact its market positioning and stakeholder interests.
More about Aditxt
Aditxt, Inc. is a social innovation platform focused on accelerating promising health innovations. The company operates an ecosystem involving research institutions, industry partners, and shareholders to drive its mission of making promising innovations possible. Aditxt currently has programs focused on immune health and precision health and plans to introduce a new program dedicated to women’s health through a merger with Evofem Biosciences, Inc.
Average Trading Volume: 2,991,220
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.52M
See more insights into ADTX stock on TipRanks’ Stock Analysis page.